Issue 2/2010
Content (23 Articles)
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials
G. Nasti, A. Ottaiano, M. Berretta, P. Delrio, F. Izzo, A. Cassata, C. Romano, G. Facchini, D. Scala, A. Mastro, G. Romano, F. Perri, R. V. Iaffaioli
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase
Andrea Réti, Éva Pap, Vilmos Adleff, András Jeney, Judit Kralovánszky, Barna Budai
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
Su Jin Lee, Jeeyun Lee, Ho Yeong Lim, Won Ki Kang, Chel Hun Choi, Jeong-Won Lee, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun, Young Suk Park
Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines
Yoshitsugu Horio, Hirotaka Osada, Junichi Shimizu, Shizu Ogawa, Toyoaki Hida, Yoshitaka Sekido
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents
Kosalaram Goteti, C. Edwin Garner, Lucas Utley, Jing Dai, Susan Ashwell, Demetri T. Moustakas, Mithat Gönen, Gary K. Schwartz, Steven E. Kern, Sonya Zabludoff, Patrick J. Brassil
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
Aleksandar Radujkovic, Stefan Fruehauf, W. Jens Zeller, Anthony D. Ho, Julian Topaly
Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
Daniel P. Greene, James Stuart Ferriss, Amir A. Jazaeri
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Kaname Yamamoto, Masatoshi Shirane, Yoriko Yamashita, Kazushige Mori
Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo
Xiaolei Ye, Wu Zhou, Yongqi Li, Yihua Sun, Yihua Zhang, Hui Ji, Yisheng Lai
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
Steven J. Cohen, Mark M. Zalupski, Manuel R. Modiano, Paul Conkling, Yehuda Z. Patt, Peg Davis, Robert T. Dorr, Michelle L. Boytim, Evan M. Hersh
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
Trine Zeeberg Buch-Hansen, Lise Bentzen, Steinbjoern Hansen, Morten Hoeyer, Niels Viggo Jensen, Charlotte Saxe, Lisa Sengeloev
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
Karol L. Thompson, Barry A. Rosenzweig, Jun Zhang, Alan D. Knapton, Ronald Honchel, Steven E. Lipshultz, Jacques Retief, Frank D. Sistare, Eugene H. Herman
Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
Valentina K. Todorova, Yihong Kaufmann, Leah J. Hennings, V. Suzanne Klimberg
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Kelley A. Sookraj, Wilbur B. Bowne, Victor Adler, Ehsan Sarafraz-Yazdi, Josef Michl, Matthew R. Pincus
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Yukimoto Ishii, Shigeru Suzuki, Yasuo Takahashi, Tadatoshi Takayama, Satoshi Asai
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
Christopher J. Sweeney, Chris Takimoto, Leslie Wood, Jennifer M. Porter, William G. Tracewell, Mona Darwish, Denise M. D’Andrea, Scot C. Remick
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen, George D. Demetri, Robert J. Motzer
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
Sun Jin Sym, Min-Hee Ryu, Hye Jin Kang, Sung Sook Lee, Heung-Moon Chang, Jae Lyun Lee, Tae Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
Yun Jung Choi, Jin Kyung Rho, Byung-suk Jeon, Su Jin Choi, Su Cheol Park, Seung Sook Lee, Hye-Ryoun Kim, Cheol Hyeon Kim, Jae Cheol Lee
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
F. Caponigro, D. Lorusso, G. Fornari, C. Barone, M. Merlano, M. Airoldi, M. Schena, R. MacArthur, S. Weitman, M. G. Jannuzzo, S. Crippa, F. Fiorentini, A. Petroccione, S. Comis
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
Emmanuel Mitry, Pascal Hammel, Gaël Deplanque, Françoise Mornex, Philippe Levy, Jean-François Seitz, Alain Moussy, Jean-Pierre Kinet, Olivier Hermine, Philippe Rougier, Eric Raymond
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
N. A. Helsby, W. Y. Lo, P. Thompson, G. R. Laking
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy
Anilkumar Katta, Mark J. Fesler, Alan Tan, Giao Vuong, John M. Richart